American Society of Hematology

Figure 4

$Figure 4. Antisclerostin antibody normalizes osteoblast numbers but does not normalize myeloid cell expansion. (A) Relative expression of sclerostin (Sost) mRNA from femur and tibia from 7-week-old control (Con) and OCY-GsαKO (KO) mice (n = 4). (B) Immunohistochemical staining for sclerostin on tibia sections from 7-week-old control and OCY-GsαKO mice (n = 3). (C) mRNA expression of Axin2 in the CD11b+ FACS-sorted myeloid cells of 7-week-old control (Con) and OCY-GsαKO (KO) mice (n = 4) in saline or antisclerostin antibody-treated mice. (D) Trabecular bone fraction, BV/TV (%), and (E) numbers of osteoblasts per bone perimeter, N.Ob/B.Pm (/mm) in antisclerostin antibody-treated control (Con) and OCY-GsαKO (KO) mice (n = 4). (F-H) PB counts showing (F) number of leukocytes, (G) % neutrophils, and (H) number of platelets in antisclerostin antibody-treated control (Con) and OCY-GsαKO (KO) mice (n = 6). Error bars represent mean ± SEM. *P < .05 by t test.$

Antisclerostin antibody normalizes osteoblast numbers but does not normalize myeloid cell expansion. (A) Relative expression of sclerostin (Sost) mRNA from femur and tibia from 7-week-old control (Con) and OCY-GsαKO (KO) mice (n = 4). (B) Immunohistochemical staining for sclerostin on tibia sections from 7-week-old control and OCY-GsαKO mice (n = 3). (C) mRNA expression of Axin2 in the CD11b⁺ FACS-sorted myeloid cells of 7-week-old control (Con) and OCY-GsαKO (KO) mice (n = 4) in saline or antisclerostin antibody-treated mice. (D) Trabecular bone fraction, BV/TV (%), and (E) numbers of osteoblasts per bone perimeter, N.Ob/B.Pm (/mm) in antisclerostin antibody-treated control (Con) and OCY-GsαKO (KO) mice (n = 4). (F-H) PB counts showing (F) number of leukocytes, (G) % neutrophils, and (H) number of platelets in antisclerostin antibody-treated control (Con) and OCY-GsαKO (KO) mice (n = 6). Error bars represent mean ± SEM. *P < .05 by t test.

This Feature Is Available To Subscribers Only